Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season
The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season.
The World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2024 influenza season in the southern hemisphere. The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.
The WHO recommends that trivalent vaccines for use in the 2024 southern hemisphere influenza season contain the following:
Egg-based vaccines
an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
an A/Thailand/8/2022 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture- or recombinant-based vaccines
an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
an A/Massachusetts/18/2022 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
